Buscar
Mostrando ítems 1-10 de 16015
Improving representativeness in trials: a call to action from the Global Cardiovascular Clinical Trialists Forum
(Oxford University Press, 2023)
Participants enrolled in cardiovascular disease (CVD) randomized controlled trials are not often representative of the population living with the disease. Older adults, children, women, Black, Indigenous and People of ...
Initiation and continuation of randomized trials after the publication of a trial stopped early for benefit asking the same study question: STOPIT-3 study design
(BioMed Central, 2013)
Background: Randomized control trials (RCTs) stopped early for benefit (truncated RCTs) are increasingly common and, on average, overestimate the relative magnitude of benefit by approximately 30%. Investigators stop trials ...
Botanical drug clinical trial: common issues and future options
Botanical drugs are plant-derived, complex mixtures which may have synergistic effects.
In order to understand this disparity between human use and drugs approved by regulatory agencies,
we analyzed botanical drug clinical ...
Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials
(BioMed Central, 2021)
Background: Convalescent plasma has been widely used to treat COVID-19 and is under investigation in numerous randomized clinical trials, but results are publicly available only for a small number of trials. The objective ...
Effectiveness of a multicomponent treatment versus conventional treatment in patients with fibromyalgia: Study protocol
(Lippincott Williams and Wilkins, 2020)
Randomized controlled trials for COVID-19: evaluation of optimal randomization methodologies - need for the data validation of the completed trials, and to improve the ongoing and future randomized trial designs
COVID-19. The Recovery trials showed an Absolute Risk Reduction (ARR) in mortality by 2.8% with
Dexamethasone, and the ACTT-1 trial showed that the treatment with Remdesivir reduced the Time to
recovery by 4 days. The ...
Treatment of Brain AVMs (TOBAS): study protocol for a pragmatic randomized controlled trial
(Trials (London), 2023)